Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nippon Chemiphar CoTSE:4539 +1.90%49 EV-to-EBITDA is 8.51 as of Sep. 01, 2026, which is 16% below its 10-year median of 10.08. GuruFocus rates TSE:4539 with a GF Score™ of 49/100 and a GF Value™ of 円1,711.04 (Fairly Valued). The stock has 6 warning signs investors should review. Among 729 Drug Manufacturers companies, Nippon Chemiphar Co ranks better than 69% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nippon Chemiphar Co's enterprise value is 円17,060 Mil.
Nippon Chemiphar Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円2,005 Mil. Therefore, Nippon Chemiphar Co's EV-to-EBITDA for today is 8.51.
The historical rank and industry rank for Nippon Chemiphar Co's EV-to-EBITDA or its related term are showing as below:
TSE:4539'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5066.91 Med: 10.08 Max: 1326.86
Current: 8.5
During the past 13 years, the highest EV-to-EBITDA of Nippon Chemiphar Co was 1326.86. The lowest was -5066.91. And the median was 10.08.
TSE:4539's EV-to-EBITDA is ranked better than 69% of 729
companies
in the Drug Manufacturers industry
Industry Median: 13.48
vs TSE:4539: 8.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nippon Chemiphar Co (TSE:4539) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nippon Chemiphar Co's PE Ratio (TTM) for today is calculated as:
Nippon Chemiphar Co's share price for today is 円1605.00.
Nippon Chemiphar Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円54.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nippon Chemiphar Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Chemiphar Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Chemiphar Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Chemiphar Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nippon Chemiphar Co's EV-to-EBITDA falls into.
Nippon Chemiphar Co's current Enterprise Value is 円17,060 Mil.
Nippon Chemiphar Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,005 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nippon Chemiphar Co (TSE:4539) has a EV-to-EBITDA of 8.51 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nippon Chemiphar Co. This is 16% below median its historical median of 10.08. According to the industry distribution chart, Nippon Chemiphar Co ranks #226 out of 729 companies in the Drug Manufacturers industry, placing it in the top 31%.
Is Nippon Chemiphar Co's EV-to-EBITDA too high?
Nippon Chemiphar Co's current EV-to-EBITDA of 8.51 is 16% below median its 10-year median of 10.08. The Drug Manufacturers industry median EV-to-EBITDA is 13.48. Nippon Chemiphar Co's value of 8.51 is 36.9% below this industry median. Based on the distribution chart, Nippon Chemiphar Co ranks #226 out of 729 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Nippon Chemiphar Co has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nippon Chemiphar Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nippon Chemiphar Co ranks #226 out of 729 companies for EV-to-EBITDA. This puts Nippon Chemiphar Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.48. Nippon Chemiphar Co's value of 8.51 is 36.9% below this benchmark. While the company's 10-year median is 10.08 vs. the industry median of 13.48, Nippon Chemiphar Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.48, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Chemiphar Co's current EV-to-EBITDA of 8.51 is 36.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nippon Chemiphar Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Chemiphar Co's current EV-to-EBITDA is 8.51, which is 16% below median its own 10-year median of 10.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Chemiphar Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Chemiphar Co (TSE:4539) is currently considered Fairly Valued. The stock's GF Value™ is 円1,711.04, compared to a current price of 円1,605.00 — trading 6.2% below its estimated fair value. The current EV-to-EBITDA is 8.51, which is 16% below median its 10-year median of 10.08 and 36.9% below the Drug Manufacturers industry median of 13.48. Nippon Chemiphar Co's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nippon Chemiphar Co (TSE:4539), the current EV-to-EBITDA is 8.51 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Chemiphar Co (TSE:4539) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Chemiphar Co stock appears to be undervalued.
The current stock price of 円1,605.00 is trading 6.2% below its estimated GF Value™ of 円1,711.04.
GuruFocus considers Nippon Chemiphar Co to be Fairly Valued.
Key valuation signals for TSE:4539:
EV-to-EBITDA: 8.51 (16% below median its 10-year median of 10.08)
GF Value™: 円1,711.04 vs. price of 円1,605.00 (6.2% below fair value)
Industry Position: 36.9% below the Drug Manufacturers median (#226 of 729)
No single metric tells the full story. See the TSE:4539 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Chemiphar Co Ltd produces and sells medicines for medical use. The company also produces medical, health and cosmetics products. Nippon Chemiphar sterilizes medical instruments for hospitals and operates nursing home for elderly.
49GF Score
Get the complete analysis for TSE:4539
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4539 has been successfully added to your 
